U.S. seeks pharmaceutical deal with Switzerland to fast-track FDA approvals
The Biden administration wants to reach a narrow sectoral trade agreement with the Swiss pharmaceutical industry, the U.S. Ambassador to Switzerland told Blick am Sonntag.
The goal of the potential accord is to make it easier for the U.S. Food and Drug Administration to approve Swiss pharmaceuticals, Scott Miller said in an interview with the newspaper published Sunday.
The U.S. imported $21 billion worth of pharmaceutical products from Switzerland last year, according to data from the Geneva-based International Trade Center.
The development comes amid stalled trade talks between the U.S. and Switzerland, which continue to disagree over market access for U.S. agricultural products into the alpine nation.
“Switzerland has decided that they cannot give us access to the agriculture market,” Miller said. “Until we get any further there, we will talk about specific sectoral agreements.”
U.S. exports of agricultural products to Switzerland were $393 million in 2019, according to the U.S. Trade Representative.
Switzerland is America’s 16th-largest goods-trading partner. Two-way goods and services trade between the U.S. and Switzerland totaled $134 billion in 2019, according to the USTR.
Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.